Research programme: anti-G protein-coupled receptor antibodies - Abilita Therapeutics
Alternative Names: Anti-G protein-coupled receptor antibodies - Ab3; Anti-G protein-coupled receptor antibodies - Ab6; Anti-G protein-coupled receptor antibodies - CCR7; Anti-G protein-coupled receptor antibodies - EP2; Anti-G protein-coupled receptor antibodies - EP4Latest Information Update: 07 Jun 2023
At a glance
- Originator Abilita Bio
- Developer Abilita Therapeutics
- Class Antibodies; Antineoplastics
- Mechanism of Action CCR7 receptor modulators; G protein-coupled receptor antagonists; Prostaglandin E EP2 receptor modulators; Prostaglandin E EP4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Cancer; CNS disorders
Most Recent Events
- 01 Jun 2023 Abilita Bio is now called Abilita Therapeutics
- 28 Oct 2020 No recent reports of development identified for research development in Breast-cancer in USA
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in USA